$2.38
2.46% yesterday
Nasdaq, Nov 25, 10:14 pm CET
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Editas Medicine, Inc. Stock price

$2.38
-0.80 25.16% 1M
-3.25 57.73% 6M
-7.75 76.51% YTD
-8.28 77.66% 1Y
-30.92 92.85% 3Y
-24.80 91.24% 5Y
-15.82 86.92% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.06 2.46%
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Key metrics

Market capitalization $196.46m
Enterprise Value $-30.14m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.16
EV/Sales (TTM) EV/Sales -0.49
P/S ratio (TTM) P/S ratio 3.18
P/B ratio (TTM) P/B ratio 1.12
Revenue growth (TTM) Revenue growth 150.95%
Revenue (TTM) Revenue $61.76m
EBIT (operating result TTM) EBIT $-228.52m
Free Cash Flow (TTM) Free Cash Flow $-191.36m
Cash position $265.09m
EPS (TTM) EPS $-2.56
P/E forward negative
P/S forward 4.58
EV/Sales forward negative
Short interest 26.45%
Show more

Is Editas Medicine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Editas Medicine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Editas Medicine, Inc. forecast:

9x Buy
50%
8x Hold
44%
1x Sell
6%

Analyst Opinions

18 Analysts have issued a Editas Medicine, Inc. forecast:

Buy
50%
Hold
44%
Sell
6%

Financial data from Editas Medicine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
62 62
151% 151%
100%
- Direct Costs 5.89 5.89
5% 5%
10%
56 56
203% 203%
90%
- Selling and Administrative Expenses 64 64
4% 4%
104%
- Research and Development Expense 214 214
39% 39%
347%
-223 -223
10% 10%
-360%
- Depreciation and Amortization 5.89 5.89
5% 5%
10%
EBIT (Operating Income) EBIT -229 -229
10% 10%
-370%
Net Profit -211 -211
8% 8%
-341%

In millions USD.

Don't miss a Thing! We will send you all news about Editas Medicine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Editas Medicine, Inc. Stock News

Neutral
Seeking Alpha
6 days ago
Editas Medicine, Inc. (NASDAQ:EDIT ) Stifel 2024 Healthcare Conference November 19, 2024 1:50 PM ET Company Participants Erick Lucera - Chief Financial Officer Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha All right. Thanks, everyone, for joining us for the next half hour.
Neutral
GlobeNewsWire
20 days ago
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December:
Neutral
GlobeNewsWire
22 days ago
Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia
More Editas Medicine, Inc. News

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Gilmore O’Neill
Employees 265
Founded 2013
Website www.editasmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today